Home > Sandhu RK > Cost-effectiveness of Apixaban vs Aspirin for the Reduction of Thrombo-Embolism in High-Risk Patients with Device-Detected Atrial Fibrillation: Insights from the ARTESiA trial.
Cost-effectiveness of Apixaban vs Aspirin for the Reduction of Thrombo-Embolism in High-Risk Patients with Device-Detected Atrial Fibrillation: Insights from the ARTESiA trial.